8-K: Strawberry Fields REIT Raises $17M in Israeli Unit Offering

Strawberry Fields REIT, Inc. announced the completion of an offering of units in Israel, comprising Series D Bonds and Series 2 Warrants, which generated approximately $17 million in gross proceeds.

Summary

• Strawberry Fields REIT, Inc. completed a private offering of units in Israel on September 15, 2026, under Regulation S exemptions.
• The offering consisted of Series D Bonds and Series 2 Warrants, raising approximately $17 million in gross proceeds.
• The Bonds carry a fixed annual interest rate of 7.5% and are repayable in four unequal annual installments between June 2027 and December 2031.
• The Series 2 Warrants are exercisable into shares of common stock at an exercise price of NIS 46 (approximately $15.12 as of September 15, 2026) and expire on December 30, 2027.
• The shares underlying the warrants are registered under an effective Form S-3 registration statement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a capital raise but is conducted through a private offering in Israel, which may limit broader investor access and visibility.

Positives

• Successfully raised approximately $17 million in gross proceeds through a debt and warrant offering.
• The offering diversifies funding sources by tapping into the Israeli market.
• The Series D Bonds offer a fixed 7.5% annual interest rate.
• The company has a clear repayment schedule for the Series D Bonds, with the final principal payment due December 31, 2031.
• The warrants provide potential for future equity dilution at a defined exercise price.

Negatives

• The offering was conducted solely within Israel under Regulation S, limiting accessibility for U.S. investors.
• The bonds and warrants are not listed on any U.S. stock exchange.
• The exercise price of the warrants is linked to the USD exchange rate and has a floor price based on the NYSE closing price.
• The company has substantial existing debt, including secured mortgage indebtedness and other secured loans, which could increase financial risk.

Risks

• The Series D Bonds are unsecured general obligations, making them subordinate to secured debt.
• The company's ability to service its debt depends on its financial and operating performance, which is subject to economic conditions.
• The company has the ability to incur substantial additional debt, which could increase financial risks.
• The market price of the securities may fluctuate, and an active trading market may not develop or last.
• The use of proceeds is for general corporate purposes, including debt repayment and asset acquisition, with management having discretion over allocation.
• The company's subsidiaries conduct a portion of its operations, and their creditors' rights are senior to the rights of Series D Bondholders.
• The company's business is subject to risks related to the national, state, and local economies, particularly in the healthcare and real estate sectors.
• The company's ability to maintain its qualification as a REIT is subject to various requirements.

Future Outlook

The filing does not provide specific forward-looking financial guidance. However, it details the terms of the Series D Bonds and Series 2 Warrants, including their maturity and exercise periods, and outlines the intended use of proceeds for ongoing operations, debt repayment, and asset acquisition.

Management Comments

• The Company intends to operate in a manner to qualify for taxation as a REIT.
• The Company may, at any time, announce by immediate report the expiration of the guarantee, provided that it receives prior confirmation from the rating agency that the rating will not be downgraded.
• The net proceeds from the issuance will be used for ongoing operations and general purposes, including the repayment of existing debts and the acquisition of assets.

Industry Context

StockSavvy.ai notes that this offering aligns with the REIT sector's ongoing need for capital to fund property acquisitions and manage existing debt. The focus on skilled nursing and post-acute healthcare properties places Strawberry Fields REIT within a specialized segment of the healthcare real estate market, which can be influenced by regulatory changes and demographic trends.

Comparison to Industry Standards

• The fixed annual interest rate of 7.5% on the Series D Bonds is competitive within the current debt markets for REITs, though specific comparisons would require analysis of similar unsecured debt issuances.
• The warrant exercise price of NIS 46 (approx. $15.12) represents a premium over the closing price of the Company's shares on the NYSE American on September 10, 2026 (approximately 9.32% higher than the closing price on NYSE and 14.83% higher than on TASE), which is a common practice to provide downside protection for the issuer.
• The repayment schedule for the Series D Bonds, with principal payments spread over several years, is a standard approach for managing long-term debt in the real estate sector.

Related Party Transactions

• The master lease agreement under the Landmark framework was amended to include two additional properties, Lincoln Park and Westshire, which were previously operated by companies affiliated with the Company's controlling shareholders under identical rental terms. The amendment increased annual base rent by approximately $2 million.

Stakeholder Impact

• Shareholders: Potential dilution from the exercise of warrants, but also potential for increased company value if proceeds are used effectively. The offering is conducted in Israel, limiting direct participation for many U.S. shareholders.
• Creditors: The unsecured nature of the Series D Bonds means they are subordinate to existing secured debt. The company's substantial existing debt level could impact its ability to service all obligations.
• Bondholders (Series D): Their investment is unsecured and subject to the company's credit risk. They have specific repayment schedules and interest rates, but are subordinate to secured creditors.
• Warrant Holders: Have the right to purchase common stock at a fixed price until December 30, 2027, with potential for profit if the stock price exceeds the exercise price.

Next Steps

• The shares underlying the warrants will be offered and sold pursuant to an effective registration statement on Form S-3.
• A prospectus supplement will be filed with the SEC regarding the shares to be issued upon exercise of the warrants.
• The Series D Bonds and Series 2 Warrants will be listed for trading on the Tel Aviv Stock Exchange Ltd (TASE).

Key Dates

Recommendation

The offering successfully raises capital, but it is a private placement in Israel with limited U.S. investor access. The company carries significant debt, and the unsecured nature of the new bonds adds risk. While the fixed interest rate is attractive, the overall financial health and the subordination of these bonds to secured debt warrant a cautious 'hold' recommendation pending further operational and financial performance.

Keywords

REIT, Bonds, Warrants, Debt Offering, Capital Raise, Israel, Regulation S, Healthcare Properties